In-Depth Review on Parkinson's Disease - Pipeline Review, H2 2016

Parkinson's Disease - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Complete report available @ Parkinson's Disease - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

2-BBB Medicines BV 4P Therapeutics LLC AbbVie Inc AC Immune SA Acelot Inc Acorda Therapeutics Inc Adamas Pharmaceuticals Inc Addex Therapeutics Ltd Advinus Therapeutics Ltd Aeolus Pharmaceuticals Inc AFFiRiS AG Amabiotics SAS Amarantus Bioscience Holdings Inc American Gene Technologies International Inc Anavex Life Sciences Corp Angita BV Antoxis Ltd Aoxing Pharmaceutical Company Inc APeT Holding BV ApoPharma Inc Aposense Ltd Araclon Biotech SL ArmaGen Inc Arrien Pharmaceuticals LLC AstraZeneca Plc AudioCure Pharma GmbH Berg LLC Bial - Portela & Ca SA Bio-Modeling Systems SAS BioArtic AB Biogen Inc BioHealthonomics Inc Biopharm GmbH Biotie Therapies Corp BrainStorm Cell Therapeutics Inc Calico LLC Cantabio Pharmaceuticals Inc Cardax Inc Carna Biosciences Inc Cell Cure Neurosciences Ltd Cellceutix Corp CHA Bio & Diostech Co Ltd Chipscreen Biosciences Ltd Clera Inc Clevexel Pharma SA Contera Pharma ApS ContraVir Pharmaceuticals Inc Corium International Inc Curemark LLC Daewoong Pharmaceutical Co Ltd Denali Therapeutics Inc Depomed Inc DermaXon LLC Diffusion Pharmaceuticals Inc Dizlin Medical Design AB Domain Therapeutics SA Edison Pharmaceuticals Inc Eli Lilly and Company Ensemble Therapeutics Corp Fabre-Kramer Pharmaceuticals Inc FPRT Bio Inc Genecode AS Generon (Shanghai) Corp Ltd Genervon Biopharmaceuticals LLC GenKyoTex SA Genmab A/S Genosco Inc Genzyme Corp H. Lundbeck A/S Harbor Therapeutics Inc Heptares Therapeutics Ltd Herantis Pharma Plc Hisamitsu Pharmaceutical Co Inc Horizon Pharma Plc Huons Co Ltd ICB International Inc Immungenetics AG Impel NeuroPharma Inc Intec Pharma ltd Integrative Research Laboratories Sweden AB InterMed Discovery GmbH International Stem Cell Corp Io Therapeutics Inc Iproteos SL Jeil Pharmaceutical Co Ltd Kainos Medicine Inc Khondrion BV KineMed Inc Kissei Pharmaceutical Co Ltd Kyowa Hakko Kirin Co Ltd Lead Discovery Center GmbH Living Cell Technologies Ltd Longevity Biotech Inc Luye Pharma Group Ltd Lysosomal Therapeutics Inc M et P Pharma AG M's Science Corp M3 Biotechnology Inc MedGenesis Therapeutix Inc MedImmune LLC MeiraGTx Ltd Merck & Co Inc Metabolic Solutions Development Company LLC Minerva Neurosciences Inc Mission Therapeutics Ltd Mitochon Pharmaceuticals Inc MitoDys Therapeutics Ltd Motac Neuroscience Ltd Netherlands Translational Research Center BV Neuralstem Inc Neuraltus Pharmaceuticals Inc Neuren Pharmaceuticals Ltd NeuroDerm Ltd NeuroNascent Inc NeurOp Inc Neuropore Therapies Inc New World Laboratories Inc Newron Pharmaceuticals SpA nLife Therapeutics SL NLS Pharma Group Novartis AG Novo Nordisk A/S NsGene A/S Omeros Corp Oncodesign SA Ono Pharmaceutical Co Ltd OPKO Health Inc Orion Oyj Oryzon Genomics SA Oxford BioMedica Plc ParkCell AB Peptron Inc Pfizer Inc Pharma Two B Ltd PharmatrophiX Inc Pharmaxis Ltd Pharmicell Co Ltd Pharnext SA Phenomenome Discoveries Inc Plex Pharmaceuticals Inc Prana Biotechnology Ltd Prexton Therapeutics SA Primary Peptides Inc Proclara Biosciences Inc Promentis Pharmaceuticals Inc Promius Pharma LLC Proteostasis Therapeutics Inc Prothena Corp Plc QR Pharma Inc reMYND NV Retrotope Inc Sage Therapeutics Inc Saje Pharma LLC SanBio Inc Saneron CCEL Therapeutics Inc Saniona AB Sellas Inc Serina Therapeutics Inc Shire Plc Sigma-Tau SpA SignPath Pharma Inc Signum Biosciences Inc SK Biopharmaceuticals Co Ltd STATegics Inc Stelic Institute & Co Inc Sun Pharma Advanced Research Company Ltd Sunovion Pharmaceuticals Inc Synthonics Inc Takara Bio Inc Takeda Pharmaceutical Company Ltd TauRx Therapeutics Ltd TechnoPhage SA Teikoku Pharma USA Inc Teva Pharmaceutical Industries Ltd Titan Pharmaceuticals Inc Trevena Inc TyrNovo Ltd UniQure NV Vanton Research Laboratory LLC Varinel Inc VistaGen Therapeutics Inc VivaCell Biotechnology Espana SL Voyager Therapeutics Inc vTv Therapeutics Inc Wellstat Therapeutics Corp

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###